PBMs and Drug Spending in 2020

July 14, 2021

This year, we review 2020 data on commercial plan sponsor clients of CVS Health and Express Scripts along with two smaller PBMs—Navitus and WellDyne. As you will see below, plan sponsors experienced another year of single-digit growth in overall pharmacy benefit drug spending.

For specialty drugs, utilization—more people taking more prescriptions—remained the driving force behind this higher spending. Specialty drug costs grew slowly—or even declined.

I’m sad to report that this year’s analysis is skimpier than usual. CVS Health has published only a bare bones summary, while Prime Therapeutics, MedImpact, and other large PBMs have stopped publishing trend reports. I document this disappointing state of affairs below.

Read more by clicking the link to the full article below.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

2026 Forecast: The Year of PBM Clarity 

2026 Forecast: The Year of PBM Clarity 

This is shaping up to be a pivotal year in health care, especially in pharmacy benefit management (PBM). With rising costs, policy reform on a national scale and growing pressure from plan sponsors and members, one theme stands out: clarity. Will 2026 be…

previous arrow
next arrow